The World Health Organization (WHO) has further delayed the emergency use authorisation (EUA) for Covaxin, the Covid vaccine developed in India, as the global body has sent more technical queries to its manufacturer Bharat Biotech, according to sources. This delay is likely to adversely affect Indians', especially students', international travel plans. Without the EUA, Covaxin will not be considered an accepted vaccine by most countries around the world. WHO's queries for Bharat Biotech comes despite the Hyderabad-based drug maker asserting that it has submitted all data required for clearance.
